0000000000181103

AUTHOR

Udo Kontny

showing 4 related works from this author

Second malignancies after treatment of childhood non-Hodgkin lymphoma: a report of the Berlin-Frankfurt-Muenster study group

2021

Haematologica : journal of the European Hematology Association 106(5), 1390-1400 (2021). doi:10.3324/haematol.2019.244780

Oncologymedicine.medical_specialtyArticle03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansCumulative incidence030304 developmental biology0303 health sciencesChildhood Cancer RegistryUnivariate analysisbusiness.industryIncidenceLymphoma Non-HodgkinMyelodysplastic syndromesIncidence (epidemiology)Lymphoblastic lymphomaMyeloid leukemiaNeoplasms Second PrimaryHematologyPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseLymphoma030220 oncology & carcinogenesisFemaleCranial Irradiationbusiness
researchProduct

Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatri…

2017

Heritable predisposition is an important cause of cancer in children and adolescents. Although a large number of cancer predisposition genes and their associated syndromes and malignancies have already been described, it appears likely that there are more pediatric cancer patients in whom heritable cancer predisposition syndromes have yet to be recognized. In a consensus meeting in the beginning of 2016, we convened experts in Human Genetics and Pediatric Hematology/Oncology to review the available data, to categorize the large amount of information, and to develop recommendations regarding when a cancer predisposition syndrome should be suspected in a young oncology patient. This review su…

0301 basic medicineHistoryMedizinGene Expression0302 clinical medicineNeoplasm Proteins/geneticsNeoplasmsChildGenetics (clinical)Societies Medicalddc:618HematologyJuvenile myelomonocytic leukemiaCancer predispositionSyndromeFocus Groups21st Century3. Good healthNeoplasm Proteins030220 oncology & carcinogenesisHematologic NeoplasmsGenetic Testing/methodsmedicine.medical_specialtyAdolescentGenetics MedicalGenetic CounselingHistory 21st CenturyMedical/history/instrumentation/methodsFamilial adenomatous polyposis03 medical and health sciencesInternal medicineGeneticsmedicineHumansFocus Groups/methodsGenetic Predisposition to DiseaseGenetic TestingIntensive care medicineGenetic Counseling/ethicsbusiness.industryHematologic Neoplasms/diagnosis/genetics/pathologyCancermedicine.diseasePediatric cancerHuman genetics030104 developmental biologyLi–Fraumeni syndromeNeoplasms/diagnosis/genetics/pathologyMutationMedical/historySocietiesbusinessAmerican journal of medical genetics. Part A
researchProduct

First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic…

2017

Recently, studies in adults with acute promyelocytic leukemia (APL) showed high cure rates in low-risk patients treated with all-trans retinoid acid (ATRA) and arsenic trioxide (ATO), while toxicities were significantly reduced compared to the standard treatment with ATRA and chemotherapy. Here we report about first experience with 11 pediatric patients with low-risk APL treated with ATRA and ATO. All patients stayed in molecular remission. All suffered from hyperleukocytosis. Two patients experienced reversible severe side effects. One suffered from osteonecroses at both femurs, seizures, as well as posterior reversible encephalopathy syndrome, the other patient had an abducens paresis.

Acute promyelocytic leukemiaMalemedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentMedizinTretinoinGastroenterologyArsenicals03 medical and health scienceschemistry.chemical_compound0302 clinical medicineArsenic TrioxideLeukemia Promyelocytic AcuteTretinoinInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansRetinoidArsenic trioxideChildneoplasmsParesisRetrospective StudiesChemotherapybusiness.industryStandard treatmentInfantPosterior reversible encephalopathy syndromeOxidesHematologymedicine.diseaseSurgeryTreatment OutcomeOncologychemistry030220 oncology & carcinogenesisChild PreschoolPediatrics Perinatology and Child HealthFemalemedicine.symptombusiness030215 immunologymedicine.drug
researchProduct

The first European interdisciplinary ewing sarcoma research summit.

2012

This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License.-- et al.

EpigenomicsCancer ResearchAlternative medicineMedizinComputingMilieux_LEGALASPECTSOFCOMPUTINGReview ArticleBioinformatics[SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologydrug screen0302 clinical medicineDrug screenCancer genomicssignallingSarcomagenesis0303 health sciencessarcomagenesisSummitgeography.geographical_feature_categoryOpinion leadershipGenomicsLaboratory resultslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisanimal models3. Good healthAnimal modelsMetastatic Ewing SarcomaOncology030220 oncology & carcinogenesis[SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]EpigeneticsSarcomaImmunotherapyPrioritizationmedicine.medical_specialty[SDV.CAN]Life Sciences [q-bio]/Cancerlcsh:RC254-28203 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/Cancer[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]medicinegenomics030304 developmental biologyMedical educationgeographyepigeneticsbusiness.industrybiomarkers[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologymedicine.diseaseClinical trialprognosisbusinessBiomarkersEwing sarcomaFrontiers in oncology
researchProduct